Results 71 to 80 of about 1,786 (140)

UK Clinical Guideline for Best Practice in the Use of Vaginal Pessaries for Pelvic Organ Prolapse

open access: yes
Neurourology and Urodynamics, Volume 45, Issue 6, Page 1113-1151, August 2026.
Claire Brown   +11 more
wiley   +1 more source

Vaginal atrophy of women in postmenopause. Results from amulticentric observational study: The AGATA study

open access: yes, 2016
Objectives: Prevalence of vulvar-vaginal atrophy (VVA) has been always investigated by phone or webinterview without any objective evaluation. Objective signs associated with symptoms of VVA are nowtermed genitourinary syndrome of menopause (GSM).
VILLA, MARIA PIA   +8 more
core   +1 more source

TX-004HR Improves Sexual Function as Measured by the Female Sexual Function Index in Postmenopausal Women With Vulvar and Vaginal Atrophy: The REJOICE Trial [PDF]

open access: yes, 2016
INTRODUCTION: TX-004HR is an investigational, applicator-free, vaginal soft gel capsule containing low-dose solubilized 17β-estradiol. The phase 3, randomized, double-blinded, placebo-controlled, multicenter REJOICE trial has shown TX-004HR to be safe ...
Mirkin, Sebastian   +15 more
core   +1 more source

Comparison of Hyaluronic Acid with Vitamin E Vaginal Pessaries on Maturation of Vaginal Epithelium in Postmenopausal Women

open access: yesMajalah-i ̒ilmī pizishkī-i jundī/shapūr, 2012
Background and Objective: Following hot flashes, the second, most common and bothersome menopausal complaint is vaginal atrophy. This symptoms causes vaginal or vulvar dryness, dyspareunia, vaginismus or itching that can significantly affect quality of ...
Sara Ziagham   +4 more
doaj  

The Tissue Selective Estrogen Complex: A Promising New Menopausal Therapy

open access: yesPharmaceuticals, 2012
Menopause is associated with health concerns including vasomotor symptoms, vulvar/vaginal atrophy (VVA), and osteoporosis. Estrogen therapy or combined estrogen-progestin therapy (EPT) are primary treatment options for menopausal symptom relief and ...
Sebastian Mirkin, Barry S. Komm
doaj   +1 more source

Ospemifene for Genitourinary Syndrome of Menopause: Patient Selection

open access: yesInternational Journal of Women's Health
Giulia Marchetti,1 Annika Taithongchai,2 Dudley Robinson2 1Urogynaecology Department, Irmandade de Misericórdia da Santa Casa de São Paulo, Sao Paulo, Brazil; 2Urogynaecology Department, King’s College Hospital, London, UKCorrespondence: Dudley Robinson,
Marchetti G, Taithongchai A, Robinson D
doaj  

Photobiomodulation in post menopause genitourinary syndrome-Study protocol for a randomized, double-blind, controlled clinical protocol.

open access: yesPLoS ONE
IntroductionGenitourinary Syndrome of Menopause (GSM) defines a set of symptoms associated with an estrogen deficit involving alterations in organs genitourinary and that results in several urinary, genital, and sexual alterations.
Silvia Regina Dos Santos Pereira   +9 more
doaj   +1 more source

Group A streptococcal vaginitis: an unrecognized cause of vaginal symptoms in adult women

open access: yes, 2011
Vaginal infection with group A streptococci (GAS) is an established cause of vaginitis amongst prepubescent girls, but largely unrecognized in adult women and therefore often misdiagnosed as vulvovaginal candidosis.
Temmerman, Marleen   +7 more
core   +1 more source

Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women [PDF]

open access: yes, 2014
Objective To examine the long-term safety of oral ospemifene, a non-estrogen tissue-selective estrogen agonist/antagonist, for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA) due to menopause.
The Ospemifene Study Group   +3 more
core  

Home - About - Disclaimer - Privacy